Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
The story did not discuss the costs of PSA tests or provide estimates of the costs for following up an increase in PSA with a biopsy. These are significant cost issues, which warranted at least a line in the story. The story didn't quantify the potential reduction in biopsies. The competing AP story was much better on this point, reporting that using rising PSA levels, 1 in 7 men would have a prostate biopsy as compared with 1 in 20 men based solely on high PSA level. This suggests that change in PSA level results in 13/20 unnecessary prostate biopsies. The story could have provided more detail on some of the possible complications resulting from prostate biopsies. It did mention anxiety from tracking PSA levels over time.

Ex Output:
Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study

Ex Input:
An analysis of canines at Britain's Crufts show - held annually since the reign of Queen Victoria - found 74 percent were in ideal condition but 26 percent were overweight. None of the animals studied were underweight, researchers from the University of Liverpool reported in the journal Veterinary Record. The team reached their conclusions after studying 1,000 images of 28 dog breeds placed between first and fifth in their class during competitions from 2001 to 2013. The issue was most pronounced in certain breeds, with 80 percent of pugs, 68 percent of Basset hounds and 63 percent of Labradors proving excessively fat. While obesity at Crufts is still less common than in the general pet population, researcher Alex German said the proportion of overweight animals was a concern because show dogs were assumed to be perfect specimens of their breed. Obesity causes significant health problems in dogs, including arthritis and diabetes.

Ex Output:
One in four dogs at top show Crufts found to be overweight.

Ex Input:
The case centers on theliabilities Chemours was saddled with after DuPont spun off its former performance chemicals unit in 2015. The judge's granted Chemours' request to pause the arbitration on Thursday, one day after he heard arguments on DuPont's dismissal motion. Chemours sued DuPont earlier this year, alleging that DuPont deliberately lowballed the cost of environmental liabilities Chemours would face in indemnifying DuPont for pollution related to man-made chemicals known as per- and polyfluoroalkyl substances, or PFAS. The chemicals have been used in firefighting foam, nonstick cookware, water-repellent clothing and many other household and personal items. They sometimes are referred to as "forever chemicals" because of their longevity in the environment. The PFAS family of chemicals, which have been associated with increased risk of cancer and other health problems, includes perfluorooctanoic acid, or PFOA, which was used in the production of Teflon. At the time of the Chemours spinoff, DuPont was facing multidistrict litigation involving 3,500 personal injury claims related to PFOA. DuPont pegged the maximum liability for those cases at $128 million. It settled 19 months later for $671 million, with DuPont agreeing to pay half the settlement amount, and up to $125 million more toward costs of other PFOA-related litigation. DuPont has argued that the lawsuit must be dismissed because the separation agreement with Chemours mandates that any disputes arising from the 2015 spinoff must be resolved through private arbitration. Chemours says it was never in the position to consent to arbitration and that the arbitration clause is therefore invalid. The judge ruled Thursday that if Chemours is correct, allowing the arbitration to proceed would force Chemours to submit to an arbitration absent a contractual obligation to do so, which he said would amount to irreparable harm to Chemours.

Ex Output:
Judge halts arbitration in Chemours-DuPont dispute.